And succeeded in making a conventional closer to the retina of a biological tissue efficiently.

From human ES cells (embryonic stem cells), it has succeeded in making a conventional closer to the retina of a biological tissue efficient, and RIKEN multicellular system formed Research Center (Kobe) Sumitomo Chemical announced. Eye of incurable disease "retinitis pigmentosa" that there is a possibility of help in regenerative medicine, such as. It has been posted on the date of the British science journal Nature online Communications 19.
Co-author of STAP cell paper, Yoshiki Sasai of RIKEN who committed suicide last year in August also participated in the study and papers created, and are contiguous to name the author.

Retina consists the viewing multiple types of cells, such as cells, for it to be difficult healing damaged, the development of regenerative medicine using ES cells and iPS cells (induced pluripotent stem cells) is expected. Sasai and colleagues in 2012, was produced a three-dimensional retina from the world's first human ES cells, there is a problem in quality, such as there is a case in which cells are not arranged in an orderly manner.
The center of Kuwabara, visiting researcher et al., The culture method of ES cells, such as adding a protein called BMP involved in the formation of nerve devised, it was changed to retinal cells in about 80% high efficiency of the organization closer to the complex retinal tissue me made. Variations in the quality of even small.
The center of Takahashi project leaders will also start to 2006 clinical trials (trials) of retinitis pigmentosa treatment using iPS cells. Takahashi said "variation in quality is small, it has become make more stably, very's useful in clinical use," issued comments that. I which may be environment will continue to be prepared for clinical.



ヒトのＥＳ細胞（胚性幹細胞）から、従来より生体の網膜に近い組織を効率的に作ることに成功したと、理化学研究所多細胞システム形成研究センター（神戸市）と住友化学が発表した。目の難病「網膜色素変性症」などの再生医療に役立つ可能性があるという。１９日付の英オンライン科学誌ネイチャーコミュニケーションズに掲載された。
　ＳＴＡＰ細胞論文の共著者で、昨年８月に自殺した理研の笹井芳樹氏も研究や論文作成に参加し、著者に名を連ねる。

　網膜は視細胞など複数種類の細胞からなり、傷つくと治癒が難しいため、ＥＳ細胞やｉＰＳ細胞（人工多能性幹細胞）を用いた再生医療の開発が期待されている。笹井氏らは２０１２年、世界で初めてヒトＥＳ細胞から立体網膜を作製したが、細胞が整然と並ばない場合があるなど品質に課題があった。
　同センターの桑原・客員研究員らは、神経の形成に関わるＢＭＰというたんぱく質を加えるなどＥＳ細胞の培養法を工夫し、約８割の高効率で網膜細胞に変化させ、複雑な網膜組織に近い組織を作った。品質のばらつきも小さいという。
　同センターの高橋プロジェクトリーダーらは、ｉＰＳ細胞を使った網膜色素変性症治療の臨床試験（治験）を１８年度にも開始する。高橋氏は「品質のばらつきが小さく、より安定的に作れるようになったことは、臨床に使う上で大変有用だ」とするコメントを出した。臨床に向けてよい環境が用意されていきますね。